Ma Pepeluali 12, 2026, ua hoʻolaha ke Kikowaena no ka Loiloi Lāʻau Lapaʻau (CDE) o ka ʻOihana Hoʻokele Huahana Lapaʻau Lahui o Kina ma Pepeluali 4 ua hāpai ʻia ʻo ENHERTU® (trastuzumab deruxtecan) no ka hoʻokomo ʻia ʻana i loko o ka Polokalamu Hoʻōla Paha no ka hoʻohana ʻana ma ke ʻano he lāʻau lapaʻau adjuvant i nā poʻe maʻi makua me ka maʻi ʻaʻai umauma mua HER2-positive i loaʻa ka maʻi invasive koena ma hope o ka lāʻau lapaʻau neoadjuvant anti-HER2. Hoʻokumu ʻia kēia hoʻoholo ma luna o ka ʻikepili hoʻohihi mai ka noiʻi DESTINY-Breast05 Phase III, i hōʻike ʻia ma ka 2025 ESMO Congress, nāna i hōʻike ua hoʻemi ʻo ENHERTU i ka pilikia o nā hanana ola ʻole invasive disease (IDFS) a i ʻole ka make ma 53% i hoʻohālikelike ʻia me T-DM1.
ʻO ENHERTU (trastuzumab deruxtecan; fam-trastuzumab deruxtecan-nxki ma US wale nō) he ADC i kuhikuhi ʻia e HER2. Hoʻolālā ʻia me ka hoʻohana ʻana i ka ʻenehana DXd ADC ponoʻī a Daiichi Sankyo, ʻo ENHERTU ke alakaʻi ADC ma ka waihona oncology o Daiichi Sankyo a me ka papahana holomua loa ma ka paepae ʻepekema ADC a AstraZeneca. Aia ʻo ENHERTU i kahi antibody monoclonal HER2 i hoʻopili ʻia i kahi helu o nā topoisomerase I inhibitor payloads (kahi exatecan derivative, DXd) ma o nā mea hoʻopili cleavable i hoʻokumu ʻia i ka tetrapeptide.
He hoʻokolohua honua, multicenter, randomized, open-label, phase 3 ʻo DESTINY-Breast05 e loiloi ana i ka pono a me ka palekana o ENHERTU (5.4 mg/kg) e kūʻē i ka trastuzumab emtansine (T-DM1) i nā poʻe maʻi me ka maʻi ʻaʻai umauma mua HER2 me ka maʻi invasive koena i loko o nā lymph node umauma a i ʻole axillary ma hope o ka lāʻau neoadjuvant a me kahi pilikia kiʻekiʻe o ka hoʻi hou ʻana. Ua wehewehe ʻia ka pilikia kiʻekiʻe o ka hoʻi hou ʻana he hōʻike me ke kanesa inoperable (ma mua o ka lāʻau neoadjuvant) a i ʻole nā lymp node axillary pathologically positive ma hope o ka lāʻau neoadjuvant.
ʻIkepili koʻikoʻi mai ka noiʻi DESTINY-Breast05:
- Ola ʻole i ka maʻi komo (IDFS): ʻO ka helu IDFS ʻekolu makahiki he 92.4% ma ka lima ENHERTU i hoʻohālikelike ʻia me 83.7% ma ka lima kaohi (T-DM1), e hōʻike ana i ka emi ʻana o ka pilikia he 53% (HR=0.47).
- Ola ʻAʻohe Maʻi (DFS): ʻO ka helu DFS ʻekolu makahiki he 92.3% ma ka lima ENHERTU i hoʻohālikelike ʻia me 83.5% ma ka lima kaohi, e hōʻike ana hoʻi i ka emi ʻana o ka pilikia he 53% (HR=0.47).
- Ka Pōpilikia Hoʻi Hou Mamao (DRFI): Ua hoʻemi ʻia e 51%, me nā helu DRFI ʻekolu makahiki he 93.9% vs. 86.1%.
- Ka Pōpilikia Metastasis o ka Lolo (BMFI): Ua hoʻemi ʻia e 36%, me nā helu BMFI ʻekolu makahiki he 97.6% vs. 95.8%.
Ua hoʻolaʻa ʻia ka ʻOihana Honua o ka Halemai Kanesa ʻo Beijing Southern Suburb no ka lawelawe ʻana i nā poʻe maʻi ma waho, e hāʻawi ana i ke kākoʻo multilingual, ka bila pololei me ka ʻinikua honua, ka hele pū ʻana me ka mea maʻi pilikino, a me nā lawelawe kūkākūkā kelepona. No nā poʻe maʻi me ka maʻi ʻaʻai umauma HER2-positive, hāʻawi ka ʻOihana Honua i kahi hui multidisciplinary o nā oncologists kiʻekiʻe e hoʻomohala i nā hoʻolālā lapaʻau adjuvant pilikino.
E kūkākūkā i kēia manawa no kahi loiloi lapaʻau:
Ka Laina Kōkua no nā Maʻi o ka Honua: 400-880-3716 (lawelawe ʻōlelo ʻelua hola, Kina/Pelekania)
Laina Pololei WeChat: 17801183037
Official Email ①: 100085_010@163.com
Backup Email ②: myimmnet@163.com
Inā he maʻi hou ʻoe i ʻike ʻia e ʻimi nei i nā hoʻolālā no ka maʻi koena ma hope o ka lāʻau neoadjuvant, a i ʻole he maʻi i hana ʻia i ke ʻoki kino a ke noʻonoʻo nei i kahi hoʻolālā lapaʻau adjuvant i hoʻonui ʻia, hiki i ka hui ʻOihana Honua ke hoʻopau koke i kahi loiloi moʻolelo lapaʻau mua a hāʻawi i nā ʻōlelo aʻoaʻo lapaʻau i kākau ʻia.
Ka manawa hoʻouna: Pepeluali-12-2026